近期,港交所的谴责公告将复宏汉霖推向舆论漩涡中心。这家背靠复星医药的创新药企,在上市六年间历经违规募资挪用、累计亏损超31亿元、高管千万年薪与零分红并存等多重争议,其暴露的治理漏洞不仅成为自身发展的桎梏,更折射出生物医药行业快速扩张背后的治理隐忧。募资管理的失控是复宏汉霖治理乱象的起点。2019年IPO后,占总募集资金29%的1.17亿美元被违规委托给包销商投资,这一交易既未提交董事会审议,也未...
Source Link近期,港交所的谴责公告将复宏汉霖推向舆论漩涡中心。这家背靠复星医药的创新药企,在上市六年间历经违规募资挪用、累计亏损超31亿元、高管千万年薪与零分红并存等多重争议,其暴露的治理漏洞不仅成为自身发展的桎梏,更折射出生物医药行业快速扩张背后的治理隐忧。募资管理的失控是复宏汉霖治理乱象的起点。2019年IPO后,占总募集资金29%的1.17亿美元被违规委托给包销商投资,这一交易既未提交董事会审议,也未...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.